Satavaptan
Chemical compound
- none
- N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
- 185913-78-4 Y
- 9810773
- 32699105 N
- AJS8S3P31H
- Interactive image
- C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
InChI
- InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+ N
- Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N N
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.[2] Development was discontinued in 2009.[3]
References
- ^ Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clinical Journal of the American Society of Nephrology. 1 (6): 1154–60. doi:10.2215/CJN.00160106. PMID 17699341.
- ^ Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D (July 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial". Hepatology. 48 (1): 204–13. doi:10.1002/hep.22293. PMID 18508290.
- ^ "Satavaptan". Adis Insight. Springer Nature Switzerland AG.
- v
- t
- e
Oxytocin and vasopressin receptor modulators
- Agonists: Peptide: Aspartocin
- Carbetocin
- Cargutocin
- Demoxytocin
- Lipo-oxytocin-1
- Merotocin
- Nacartocin
- Oxytocin
- PF-06478939
- PF-06655075 (PF1)
- TGOT
- Vasotocin (argiprestocin); Non-peptide: CA7
- LIT-001
- TC OT 39
- WAY-267464
- WJ0679
- Antagonists: Peptide: Atosiban
- Tocinoic acid; Non-peptide: Barusiban
- Cligosiban
- Epelsiban
- Erlosiban
- IX-01
- L-368,899
- L-371,257
- L-372,662
- Nolasiban
- Retosiban
- SSR-126768
- WAY-162720
- Catabolism inhibitors: Amastatin
- Bestatin (ubenimex)
- EDTA
- L-Methionine
- Leupeptin
- o-Phenanthroline
- Phosphoramidon
- Puromycin
V1A |
|
---|---|
V1B |
|
V2 |
|
Unsorted |
|
- Carrier proteins: Neurophysin (I, II)
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e